|Table of Contents|

Research advances on the relationship between cytochrome p450 family gene polymorphism and tamoxifen clinical efficacy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 04
Page:
696-699
Research Field:
Publishing date:

Info

Title:
Research advances on the relationship between cytochrome p450 family gene polymorphism and tamoxifen clinical efficacy
Author(s):
Xu Xinyuan; Cai Li
Department of Medical Oncology,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China.
Keywords:
tamoxifen; cytochrome p450; gene polymorphism
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2019.04.040
Abstract:
Tamoxifen is widely used in breast cancer patients with positive estrogen-receptor, it can significantly reduce the recurrence and mortality of the patients, and becomes the standard drug for anti-estrogen.The p450 enzyme is a key enzyme in tamoxifen metabolism, which affects its therapeutic effect. However,there was a high degree of variation in the reaction between individuals to tamoxifen,which was closely related to the gene polymorphism of the p450 family.In this paper,the relationship between the polymorphism of CYP2D6,CYP3A4/5,CYP2C19 gene and the metabolism and efficacy of tamoxifen was briefly described.

References:

［1］Ziaei S.Dietary isoflavones and breast cancer risk［J］.Medicines (Basel,Switzerland),2017,4(2):301-311.
［2］Leung EY,Askarian-Amiri ME,Sarkar D,et al.Endocrine therapy of estrogen receptor-positive breast cancer cells:Early differential effects on stem cell markers［J］.Frontiers in Oncology,2017,7:184.
［3］De Vries Schultink AH,Zwart W,Linn SC,et al.Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen［J］.Clinical Pharmacokinetics,2015,54(8):797-810.
［4］Damkier P,Kjaersgaard A,Barker KA,et al.CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the international tamoxifen pharmacogenomics consortium dataset［J］.Scientific Reports,2017,7(1):7727.
［5］Ter Heine R,Binkhorst L,de Graan AJ,et al.Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen［J］.British Journal of Clinical Pharmacology,2014,78(3):572-586.
［6］Antunes MV,de Oliveira V,Raymundo S,et al.CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen［J］.Pharmacogenomics,2015,16(6):601-617.
［7］Sanchez Spitman AB,Moes DJAR,Gelderblom H,et al.Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifenmetabolism［J］.European Journal of Clinical Pharmacology,2017,73(12):1589-1598.
［8］Teft WA,Gong IY,Dingle B,et al.CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy［J］.Breast Cancer Research and Treatment,2013,139(1):95-105.
［9］Charoenchokthavee W,Areepium N,Panomvana D.Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients［J］.Breast Cancer (Dove Medical Press),2017,9:249-256.
［10］Zhang YX,Li YF,Chen B,et al.Correlation between polymorphisms of CYP3A5 and CYP2D6 genotypes with concentrations of Tamoxifen and its activity metabolism 4-hydroxytamoxifen in Chinese breast cancer patients［J］.China Pharmacist,2010,13(09):1229-1232.［张宇馨,李亚芬,陈冰,等.中国CYP3A5和CYP2D6基因多态性与他莫昔芬及其活性代谢物药浓度的相关性［J］.中国药师,2010,13(09):1229-1232.］
［11］Goetz MP,Rae JM,Suman VJ,et al.Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes［J］.Journal of Clinical Oncology,2005,23(36):9312-9318.
［12］Schroth W,Antoniadou L,Fritz P,et al.Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes［J］.Journal of Clinical Oncology,2007,25(33):5187-5193.
［13］Sensorn I,Sirachainan E,Chamnanphon M,et al.Association of CYP3A4/5,ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen［J］.Pharmacogenomics and Personalized Medicine,2013,6:93-98.
［14］Wegman P,Elingarami S,Carstensen J,et al.Genetic variants of CYP3A5,CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer［J］.Breast Cancer Research,2007,9(1):R7.
［15］Lim JS,Chen XA,Singh O,et al.Impact of CYP2D6,CYP3A5,CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients［J］.British Journal of Clinical Pharmacology,2011,71(5):737-750.
［16］Powers JL,Buys SS,Fletcher D,et al.Multigene and drug interaction approach for tamoxifen metabolite patterns reveals possible involvement of CYP2C9,CYP2C19,and ABCB1［J］.Journal of Clinical Pharmacology,2016,56(12):1570-1581.
［17］Saladores P,Mürdter T,Eccles D,et al.Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer［J］.The Pharmacogenomics Journal,2015,15(1):84-94.
［18］van Schaik RH,Kok M,Sweep FC,et al.The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients［J］.Pharmacogenomics,2011,12(8):1137-1146.
［19］Beelen K,Opdam M,Severson TM,et al.CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment［J］.Breast Cancer Research and Treatment,2013,139(3):649-655.
［20］Mwinyi J,Vokinger K,Jetter A,et al.Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifentherapy［J］.Cancer Chemotherapy and Pharmacology,2014,73(6):1181-1188.
［21］Goetz MP.CYP2D6 genotype and tamoxifen:considerations for proper nonprospective studies［J］.Clinical Pharmacology and Therapeutics,2014,96(2):141-144.
［22］Pesenti C,Gusella M,Sirchia SM.Germline oncopharmacogenetics, a promising field in cancer therapy［J］.Cellular Oncology (Dordrecht),2015,38(1):65-89.
［23］Blackburn HL,Ellsworth DL,Shriver CD.Role of cytochrome p450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis,metabolism,and response to endocrine therapy［J］.Cancer Causes & Control,2015,26(3):319-332.
［24］Markopoulos C,Kykalos S.Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen［J］.World Journal of Clinical Oncology,2014,5(3):374-381.
［25］Lei L,Wang X,Wu XD,et al.Association of CYP2D6*10 (c100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population［J］.American Journal of Translational Research,2016,8(8):3585-3592.
［26］Irvin WJ,Walko CM,Weck KE,et al.Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study［J］.Journal of Clinical Oncology,2011,29(24):3232-3239.
［27］Kiyotani K,Mushiroda T,Imamura CK,et al.Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancerpatients［J］.Breast Cancer Research and Treatment,2012,131(1):137-145.
［28］Dezentjé VO,van Schaik RH,Vletter-Bogaartz JM,et al.CYP2D6 genotype in relation to tamoxifen efficacy in a dutch cohort of the tamoxifenexemestane adjuvant multinational (TEAM) trial［J］.Breast Cancer Research and Treatment,2013,140(2):363-373.
［29］Hertz DL,Kidwell KM,Hilsenbeck SG,et al.CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen:results from a population-based study［J］.Breast Cancer Research and Treatment,2017,166(1):277-287.
［30］Goetz MP,Suman VJ,Hoskin TL,et al.CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8［J］.Clinical Cancer Research,2013,19(2):500-507.
［31］Ramón y Cajal T,Altés A,Paré L,et al.Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment［J］.Breast Cancer Research and Treatment,2010,119(1):33-38.
［32］Bijl MJ,van Schaik RH,Lammers LA,et al.The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users［J］.Breast Cancer Research and Treatment,2009,118(1):125-130.

Memo

Memo:
-
Last Update: 1900-01-01